Share Email Print
cover

Proceedings Paper

Combination of vascular targeting PDT with combretastatin A4 phosphate
Author(s): Chong He; Babasola Fateye; Bin Chen
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Tumor vasculature is an attractive target for cancer therapy due to its accessibility to blood-borne therapeutic agents and the dependence of tumor cells on a functional blood supply for survival and growth. Vascular targeting photodynamic therapy (vPDT) is a novel modality based on the selective laser light activation of photosensitizers localized inside tumor vasculature to shutdown tumor vascular function. Although this vascular targeting therapy is showing great promise for cancer treatment, tumor recurrence has been observed in both preclinical and clinical studies. In this study, we intend to enhance the therapeutic outcome of vascular targeting PDT by combining it with combretastatin A4 phosphate (CA4P), a blood flow inhibitor. We found that the combination of CA4P and vPDT significantly increased endothelial cell apoptosis than each single therapy. Western blot analysis suggests that myosin light chain kinase (MLCK) is a common target of CA4P and vPDT. In a PC-3 prostate tumor model, we found that CA4P was able to greatly enhance tumor response to vPDT. These results demonstrate that CA4P and vPDT can be combined to enhance the therapeutic effect.

Paper Details

Date Published: 13 July 2009
PDF: 6 pages
Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 738032 (13 July 2009); doi: 10.1117/12.822969
Show Author Affiliations
Chong He, Univ. of the Sciences in Philadelphia (United States)
Babasola Fateye, Univ. of the Sciences in Philadelphia (United States)
Bin Chen, Univ. of the Sciences in Philadelphia (United States)


Published in SPIE Proceedings Vol. 7380:
Photodynamic Therapy: Back to the Future
David H. Kessel, Editor(s)

© SPIE. Terms of Use
Back to Top